Given that Pirfenidone is metabolised in the CYP1A2 enzyme pathway, any drug which inhibits this enzyme is likely to precipitate the toxicity of pirfenidone: concomitant therapy is to be averted. Whilst GB1275 hasn't been assessed to date in animal designs of prostate, colorectal, gastric, or esophageal cancers, There exists a https://matta332ozj4.wikijm.com/user